Estrace and Interstitial lung disease - a phase IV clinical study of FDA data

Summary:

Interstitial lung disease is reported as a side effect among people who take Estrace (estradiol), especially for people who are female, 50-59 old, have been taking the drug for 10+ years also take Fosamax, and have Osteoporosis.

The phase IV clinical study analyzes which people have Interstitial lung disease when taking Estrace. It is created by eHealthMe based on reports of 16,282 people who have side effects when taking Estrace from the FDA, and is updated regularly.

What is Estrace?

Estrace has active ingredients of estradiol. It is often used in hormone replacement therapy. eHealthMe is studying from 16,703 Estrace users. Check the latest studies of Estrace.

What is Interstitial lung disease?

Interstitial lung disease is found to be associated with 1,500 drugs and 1,839 conditions by eHealthMe. Check the latest studies of Interstitial lung disease.

On Jul, 07, 2026

16,282 people reported to have side effects when taking Estrace.
Among them, 31 people (0.19%) have Interstitial lung disease.

Could Estrace cause Interstitial lung disease?

Among these 31 people:

How long have people been on Estrace when they have Interstitial lung disease? *

What is the gender of people who have Interstitial lung disease when taking Estrace? *

female: 100 %
male: 0.0 %

What is the age of people who have Interstitial lung disease when taking Estrace? *

What are other drugs people take besides Estrace? *

What are other side effects people have besides Interstitial lung disease? *

Urinary Tract Infection: 18 people, 58.06%
Pneumonia: 14 people, 45.16%
Femur Fracture: 11 people, 35.48%
Asthma: 11 people, 35.48%
Low Turnover Osteopathy (slow removal of old bone and its replacement by new bone): 11 people, 35.48%
Blood Potassium Decreased: 10 people, 32.26%
Dyspnea (difficult or laboured breathing): 10 people, 32.26%
Irritable Bowel Syndrome: 10 people, 32.26%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 9 people, 29.03%
Bronchiectasis (abnormal widening of the bronchi or their branches, causing a risk of infection): 9 people, 29.03%

What are the existing conditions these people have? *

Osteopenia (a condition where bone mineral density is lower than normal): 11 people, 35.48%
Osteoporosis (bones weak and more likely to break): 11 people, 35.48%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 5 people, 16.13%
Weight Decreased: 4 people, 12.90%
Pain In Jaw: 4 people, 12.90%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 4 people, 12.90%
Atrophic Vulvovaginitis (inflammation of the vulva): 3 people, 9.68%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 3 people, 9.68%
Idiopathic Pulmonary Fibrosis (chronic lung disease): 3 people, 9.68%
Pulmonary Hypertension (increase in blood pressure in the lung artery): 3 people, 9.68%

* Approximation only. Some reports may have incomplete information.

Do you take Estrace and have Interstitial lung disease?

- Check whether Interstitial lung disease is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Estrace:

Estrace (16,703 reports)

Browse all side effects of Estrace:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Interstitial lung disease:

Interstitial lung disease (1,500 drugs)

Browse all the conditions that are associated with Interstitial lung disease:

Interstitial lung disease (1,839 conditions)

Related publications that referenced our studies

Thangakunam B, Christopher DJ, Mathews V, Srivastava A, "Mesenchymal stromal stem cell therapy in advanced interstitial lung disease-Anaphylaxis and short-term follow-up", Lung India: official organ of Indian Chest Society, 2015 Jan .
Kato, M., Oiso, N., Nozaki, Y., Inoue, A., Hosono, Y., Funauchi, M., ... & Kawada, A., "Antitumor necrosis factor alpha inhibitor‐induced dermatomyositis and interstitial lung disease with anti‐PL 12 autoantibody: Signs of antisynthetase syndrome", The Journal of dermatology, 2012 Jan .
Thangakunam B, Christopher DJ, Mathews V, Srivastava A, "Mesenchymal stromal stem cell therapy in advanced interstitial lung disease-Anaphylaxis and short-term follow-up", Lung India: official organ of Indian Chest Society, 2015 Jan .
Kato, M., Oiso, N., Nozaki, Y., Inoue, A., Hosono, Y., Funauchi, M., ... & Kawada, A., "Antitumor necrosis factor alpha inhibitor‐induced dermatomyositis and interstitial lung disease with anti‐PL 12 autoantibody: Signs of antisynthetase syndrome", The Journal of dermatology, 2012 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on estradiol (the active ingredients of Estrace) and Estrace (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.